Komal Jhaveri, MD, FACP

Articles

Managing Abemaciclib-Associated Toxicities in HR+/HER2- Early Breast Cancer

July 11th 2023

VK Gadi, MD, PhD, shares his strategies for managing adverse events related to abemaciclib in the treatment of HR+/HER2- breast cancer.

Recent Data on Adjuvant Therapies in HR+/HER2- Breast Cancer

July 11th 2023

Experts on HR+/HER2- breast cancer review data updates on adjuvant therapies from the 2023 ASCO Annual Meeting.

Circulating Tumor DNA as a Prognostic Marker in HR+/HER2- Breast Cancer

July 4th 2023

A discussion on the use of circulating tumor DNA (ctDNA) as a prognostic biomarker in HR+/HER2- breast cancer.

Recent Data on Neoadjuvant Therapy in HR+/HER2- Breast Cancer

July 4th 2023

The expert panel reviews data updates on neoadjuvant therapy in HR+/HR2- early breast cancer and discusses the role of CDK4/6 inhibition in this setting.

Unmet Needs in Early-Stage HR+/HER2- Breast Cancer

June 27th 2023

Experts on HR+/HER2- breast cancer discuss unmet needs in the early-stage setting.

Standard-of-Care Treatment Approaches for HR+/HER2 Early Breast Cancer

June 27th 2023

A panel of expert oncologists review standard-of-care treatment approaches for HR+/HER2- early breast cancer and genetic testing practices when utilizing PARP inhibitors.

Dr Jhaveri on RLY-2608 in PIK3CA-Mutant Advanced Breast Cancer

April 27th 2023

Komal Jhaveri, MD, FACP, discusses findings from the dose-escalation portion of the first-in-human phase 1 ReDiscover trial (NCT05216432) of the PI3Kα inhibitor RLY-2608 in patients with PIK3CA-mutant advanced breast cancer.

Emerging Concepts in mBC Treatment

March 2nd 2023

Paolo Tarantino, MD, highlights additional abstracts from SABCS 2022 that he found particularly interesting.

Investigational ADCs for Treatment of TNBC

March 2nd 2023

Komal Jhaveri, MD, FACP, explains the potential role ADCs may have in the future of breast cancer treatment.

The Role of ADCs in the Treatment of TNBC

February 22nd 2023

Dr Jhaveri explains her thoughts on sequencing ADCs in the treatment of triple-negative breast cancer.

Standard Practices for the Management of Triple-Negative Breast Cancer (TNBC)

February 22nd 2023

Drs Jhaveri and Tarantino discuss the standard of practice for managing triple negative breast cancer.

The Role of Capivasertib in ER+/HER- mBC

February 13th 2023

Komal Jhaveri, MD, FACP, discusses the role of capivasertib in ER-positive HER2-negative mBC and the design and outcomes of the CAPItello 291 trial.

Use of Second-Generation Oral SERDs in ER+/HER2- mBC

February 7th 2023

Dr Komal Jhaveri highlights important data on oral SERDs for ER-positive HER2-negative mBC that was presented at recent meetings.

Standards of Care in the Frontline Treatment of ER+/HER2- mBC

January 30th 2023

Komal Jhaveri, MD, FACP, explains data on the frontline standard of care treatment approaches for ER-positive HER2-negative mBC.

Overview of ER+/HER2- Metastatic Breast Cancer (mBC)

January 30th 2023

Paolo Tarantino, MD, provides an overview of ER-positive, HER2-negative metastatic breast cancer (ER+/HER2- mBC), highlighting the prevalence, patient populations, and the typical prognosis.

Audience Q&A: Future Directions in Breast Cancer Care

August 31st 2022

Closing out the discussion on molecular targets and clinical trials in breast cancer, expert oncologists take time to field questions from the live audience.

TROPiCS-02: Sacituzumab Govitecan in HR+/HER2- Breast Cancer

August 24th 2022

A brief review of data from the TROPiCS-02 clinical trial, which evaluated sacituzumab govitecan in HR+/HER2- metastatic or inoperable breast cancer.

DESTINY-Breast04: T-DXd in HER2-Low Metastatic Breast Cancer

August 24th 2022

Expert perspectives on the use of trastuzumab deruxtecan in HER2-low metastatic breast cancer in the context of the DESTINY-Breast04 trial.

HER2CLIMB: Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer

August 17th 2022

Focusing on the HER2CLIMB trial in HER2+ metastatic breast cancer, expert oncologists consider the value of a tucatinib-based regimen in this setting.

DESTINY-Breast03: T-DXd in Previously Treated HER2+ Breast Cancer

August 17th 2022

Comprehensive discussion on the DESTINY-Breast03 clinical trial evaluating trastuzumab deruxtecan in patients with previously treated HER2+ metastatic breast cancer.